ATE397669T1 - Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase - Google Patents

Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase

Info

Publication number
ATE397669T1
ATE397669T1 AT03761600T AT03761600T ATE397669T1 AT E397669 T1 ATE397669 T1 AT E397669T1 AT 03761600 T AT03761600 T AT 03761600T AT 03761600 T AT03761600 T AT 03761600T AT E397669 T1 ATE397669 T1 AT E397669T1
Authority
AT
Austria
Prior art keywords
drug
hiv
drug resistance
phenotypical
reverse transcriptase
Prior art date
Application number
AT03761600T
Other languages
English (en)
Inventor
Hilde Azijn
Bethune Marie-Pierre T M M De
Johan Vingerhoets
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Application granted granted Critical
Publication of ATE397669T1 publication Critical patent/ATE397669T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT03761600T 2002-07-01 2003-06-30 Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase ATE397669T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39300502P 2002-07-01 2002-07-01

Publications (1)

Publication Number Publication Date
ATE397669T1 true ATE397669T1 (de) 2008-06-15

Family

ID=30000959

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03761600T ATE397669T1 (de) 2002-07-01 2003-06-30 Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase

Country Status (7)

Country Link
US (2) US7473524B2 (de)
EP (1) EP1522039B1 (de)
AT (1) ATE397669T1 (de)
AU (1) AU2003251732B2 (de)
CA (1) CA2490764C (de)
DE (1) DE60321466D1 (de)
WO (1) WO2004003223A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01012270A (es) * 1999-05-28 2003-06-24 Virco Nv Nuevos perfiles mutacionales en la transcriptasa reversa de vih-1 correlacionadas con resistencia fenotipica a farmacos.
AU2002226316B2 (en) * 2000-10-20 2008-06-26 Virco Bvba Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
US20050214744A1 (en) * 2002-07-01 2005-09-29 Hilde Azjin New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
CA2490764C (en) * 2002-07-01 2011-11-22 Tibotec Pharmaceuticals Ltd. New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
EP1520247B1 (de) * 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
EP2142650B1 (de) * 2007-04-10 2013-05-22 Emory University Neue hiv-1-reverse-transkriptase-codon-deletion und verwendung davon bei der handhabung und behandlung von hiv-infektionen

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US327742A (en) 1885-10-06 Machine for making nuts
DE3235565A1 (de) 1982-09-25 1984-03-29 Boehringer Ingelheim KG, 6507 Ingelheim Piperidinderivate, ihre herstellung und verwendung
JPS5974341A (ja) 1982-10-19 1984-04-26 Nissan Motor Co Ltd 車両用アクセル制御装置
GB2229340B (en) 1989-03-17 1994-02-09 Technophone Ltd Radio telephone system
GB8918226D0 (en) 1989-08-09 1989-09-20 Wellcome Found Dna assays
EP0428000A1 (de) 1989-11-03 1991-05-22 Abbott Laboratories Fluorogene Substrate zum Nachweis von proteolytischer Enzymaktivität
US5235039A (en) 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
WO1993023574A1 (en) * 1992-05-14 1993-11-25 Kozal Michael J Polymerase chain reaction assays for monitoring antiviral therapy
US6063562A (en) 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
BR9704637A (pt) 1996-01-26 1998-06-09 Innogenetics Nv Processo para deteção de mutações induzidas por droga no gene de transcrição reversa
HU226203B1 (en) * 1996-01-26 2008-06-30 Virco B V B A Method for determining of the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains
ES2175355T3 (es) 1996-01-29 2002-11-16 Virologic Inc Composiciones y metodos para determinar la susceptibilidad y la resistencia a farmacos antivirales y rastreo de farmacos antivirales.
JP3062459B2 (ja) 1996-08-14 2000-07-10 理化学研究所 ポリエステル重合酵素遺伝子及びポリエステルの製造方法
BR9911600A (pt) 1998-05-26 2001-02-13 Virologic Inc Recursos e métodos para monitoração de terapia antiretroviral inibidora de transcriptase reversa de não nucleosìdeo
WO1999061666A1 (en) 1998-05-28 1999-12-02 Visible Genetics Inc. Use of polymorphisms as a predictor of drug-resistance mutations
PT2336134T (pt) 1998-06-23 2016-10-19 The Board Of Trustees Of The Univ Of Illionis Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
CN1154747C (zh) 1998-06-24 2004-06-23 病毒科学公司 监控核苷类逆转录酶抑制剂抗逆转录病毒治疗和在治疗hiv/aids中指导治疗决定的途径与方法
CA2330234A1 (en) 1998-06-24 1999-12-29 Innogenetics N.V. Method for detection of drug-selected mutations in the hiv protease gene
MXPA01012270A (es) 1999-05-28 2003-06-24 Virco Nv Nuevos perfiles mutacionales en la transcriptasa reversa de vih-1 correlacionadas con resistencia fenotipica a farmacos.
EP1194587A4 (de) 1999-06-22 2005-07-06 Virologic Inc Mittel und verfahren zum überwachen von antiretroviralen therapien mit proteaseinhibitorenund entscheidungshilfe bei therapien in der behandlung von hiv/aids
WO2000078994A1 (en) 1999-06-23 2000-12-28 The Penn State Research Foundation Compositions and methods for the quantification of sterol biosynthetic flux
WO2001079540A2 (en) 2000-04-18 2001-10-25 Virco Bvba Methods for measuring drug resistance
CA2406830C (en) 2000-04-20 2012-10-02 Virco Bvba Method for mutation detection in hiv using pol sequencing
US7058616B1 (en) * 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
US20030190603A1 (en) * 2000-06-08 2003-10-09 Brendan Larder Method and system for predicting therapeutic agent resistance and for defining the genetic basis of drug resistance using neural networks
WO2002022076A2 (en) 2000-09-15 2002-03-21 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
ATE422049T1 (de) 2000-10-20 2009-02-15 Virco Bvba Festlegen von kritischen biologischen werten zur voraussage einer therapieresistenz
AU2002226316B2 (en) * 2000-10-20 2008-06-26 Virco Bvba Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
JP2002199890A (ja) 2000-10-23 2002-07-16 Inst Of Physical & Chemical Res 生分解性ポリエステル合成酵素の改変方法
JP2005500003A (ja) 2000-11-10 2005-01-06 バイオオーリアンス ファーマ ヒト免疫不全ウイルス（ｈｉｖ）の表現型特性の新規な分析法
EP1370543B1 (de) 2001-02-14 2006-10-25 Tibotec Pharmaceuticals Ltd. Breitspektrum 2-(substituierte-amino)-benzothiazol-sulfonamide hiv protease inhibitoren
EP1319738A1 (de) * 2001-12-17 2003-06-18 Atofina Research S.A. Modifizierte Polyolefinfasern
EP1520247B1 (de) * 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
CA2490764C (en) * 2002-07-01 2011-11-22 Tibotec Pharmaceuticals Ltd. New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
RU2357962C2 (ru) 2002-09-06 2009-06-10 Элан Фармасьютикалз, Инк. Пролекарственные производные 1,3-диамино-2-гидроксипропана
EP1605064A1 (de) 2004-06-07 2005-12-14 UMC Utrecht Holding B.V. HIV Varianten, welche einen neuen Resistenzmechanismus gegenüber Proteaseinhibitoren zeigen, diagnostische Assays zum Nachweis der Varianten, und Methoden zur Identifikation von Medikamenten, welche gegen die resistenten Varianten wirksam sind.

Also Published As

Publication number Publication date
WO2004003223A2 (en) 2004-01-08
US20090061420A1 (en) 2009-03-05
US7473524B2 (en) 2009-01-06
AU2003251732B2 (en) 2008-09-18
WO2004003223A3 (en) 2005-02-17
AU2003251732A1 (en) 2004-01-19
EP1522039A2 (de) 2005-04-13
CA2490764C (en) 2011-11-22
DE60321466D1 (de) 2008-07-17
US20050239053A1 (en) 2005-10-27
US8076062B2 (en) 2011-12-13
CA2490764A1 (en) 2004-01-08
EP1522039B1 (de) 2008-06-04

Similar Documents

Publication Publication Date Title
BR0011555A (pt) Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga
ATE432506T1 (de) Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
GB0712154D0 (en) Method for evaluating correlations between structured and normalized information on genetic variations between humans and their personal clinical patient data
WO2007061881A3 (en) Systems and methods for the biometric analysis of index founder populations
Van Egeren et al. Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein
DE60321466D1 (de) Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
Bartlett et al. HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
MXPA03003476A (es) Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco.
ATE375400T1 (de) Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren
Zhao et al. Phylogenetic estimation of the viral fitness landscape of HIV-1 set-point viral load
WO2002022076A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
Safina et al. Molecular epidemiology of HIV-1 in Oryol oblast, Russia
Kostaki et al. Validation of molecular clock inferred HIV infection ages: Evidence for accurate estimation of infection dates
ES2609479T3 (es) Procedimiento implementado por ordenador y sistema informático para la identificación de organismos
EP1407042A4 (de) Mittel und verfahren zur überwachung einer antiretroviralen proteaseinhibitortherapie und als richtschnur für therapeutische entscheidungen bei der behandlung von hiv/aids
Zhao et al. Directional predictions of HIV transmission with optimised genomics in cohorts of serodiscordant couples
Mertz Finding new ways to analyze the microbiome
Zheng et al. Comparison of two‐phase analyses for case–control genetic association studies
Lasek-Nesselquist et al. A statewide analysis of SARS-CoV-2 transmission in New York
Metsky et al. Capturing diverse microbial sequence with comprehensive and scalable probe design
KR200208239Y1 (ko) 특정인의 ｄｎａ구조를 형상화한 팔찌
GB2520021A (en) HCV genotyping algorithm
WO2002022781A3 (en) Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy
Guessous et al. Trends in pharmacogenomic epidemiology: 2001–2007

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1522039

Country of ref document: EP